Bioflex Technologies to Change Its Name to Relevium Technologies Inc.

MONTREAL, QUEBEC--(Marketwired - Oct. 29, 2015) - Bioflex Technologies Inc. (TSX VENTURE:BFT)(FRANKFURT:6BX) (the "Company" or "Bioflex") announced a corporate rebrand and name change to Relevium Technologies Inc. ("Relevium") in order to better reflect its overall corporate strategy. The name change is subject to shareholder approval and it will be proposed to shareholders at the annual and special meeting of the Company, which is scheduled to take place on December 17^th 2015.

Relevium Technologies will focus on becoming a leading player in three verticals: Pain Relief, Injury Recovery and Performance through the acquisition of businesses and/or technologies all within the scope of health and wellness. The company plans to launch its new corporate website www.releviumcorp.com subsequent to this news release. The company's stock trading symbol will remain "BFT" until a change is announced.

Bioflex Technologies Inc., the corporation's first technology acquisition, will become a wholly owned subsidiary of Relevium Technologies Inc., operating independently from other potential future acquisitions. Management is actively engaged in reviewing potential acquisitions targets. In order to facilitate the process the board of directors will elect an advisory group to assist in the selection, negotiation and integration of future acquisitions.

Leena Lakdawala, CEO stated: "Relevium Technologies strategy demonstrates our commitment to creating value in Pain Relief, Recovery and Performance markets, all well-defined verticals under Health and Wellness. We are focused on acquiring and/or licencing growth businesses within these markets and we are currently evaluating multiple opportunities in this space."

The company also announced that the Board of Directors has granted Kristine Dorward a total of 200,000 stock options pursuant to the terms of the Company's incentive stock option plan. The options are exercisable to acquire common shares of the Company for a period of 10 years from the date of grant at a price of $0.15 per share. The foregoing options vest in equal tranches over a period of 18 months.

About Bioflex Technologies Inc.

Bioflex Technologies owns patented intellectual property for application on direct-to-consumer devices which aid in decreasing pain, improving recovery time and enhancing performance. The company has developed and plans to commercialize several product applications including those specific for knees, elbows, ankles and back. The company is currently developing other products including a line of sleep and wellness products; all designed to enhance physical well-being.

The Company intends to sell its products through several channels including direct, web-based sales; corporate partnerships; television shopping channels; retail distribution; internet catalogs; and through a network of distributors worldwide.

On Behalf of the Board of Directors

BIOFLEX TECHNOLOGIES INC.

Leena Lakdawala, CEO and Director

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the business and operations of the Company. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; delay or failure to receive board, shareholder or regulatory approvals; and the ability of the Company to execute and achieve its business objectives. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.